Supernus Pharmaceuticals, Inc.

This study looks at the long-term safety and effectiveness of an investigational drug called SPN-817 for adults with focal onset seizures. About 100 people who completed a previous SPN-817 study will take the drug for one year. Researchers will track side effects and changes in s…

This study tests a new medicine called SPN-817 in 60 adults whose seizures are not controlled by current treatments. The main goal is to see if the drug is safe and tolerable. Researchers will also track how much seizure frequency changes during the study.

This study tests whether a medication called SPN-812 (viloxazine extended release) can safely reduce ADHD symptoms in children aged 4 to 5. About 286 kids will receive either the drug or a placebo for 6 weeks. The goal is to see if the drug improves attention and reduces hyperact…

This study tests whether a new drug called SPN-821 can help adults with major depression when added to their current antidepressant. About 230 people will receive either SPN-821 or a placebo for 29 days. The main goal is to see if the drug reduces depression symptoms more than pl…

This study follows 120 people with Parkinson's disease who are using a continuous apomorphine infusion pump (ONAPGO™) to manage their symptoms. Researchers will track how long it takes to find the right dose, how often other Parkinson's medications need to be adjusted, and how pa…